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Effect of statin treatment on short term mortality after
pneumonia episode: cohort study
Ian Douglas, lecturer in epidemiology, Stephen Evans, professor of pharmacoepidemiology, Liam Smeeth,
professor of clinical epidemiology
ABSTRACT
Objective To determinewhether statins protect against all
cause mortality after a diagnosis of pneumonia.
Design Cohort study using propensity score based
method to control for differences between people
prescribed and not prescribed statins.
Setting United Kingdom Health Improvement Network
database, which contains electronic primary caremedical
records of more than six million patients.
Participants Every patient starting a statin between 1995
and 2006 (129288) matched with up to five non-statin
users (n=600241); 9073 patients had a recorded
diagnosis of pneumonia, of whom 1398 were using a
statin.
Main outcome measure All cause mortality within six
months of diagnosis of pneumonia.
Results Among users and non-users of statins with
comparable propensity scores, 95/942 users and 686/
3615 non-users died on the day that pneumonia was
diagnosed. In the following six month period, 109/847
statin users died compared with 578/2927 non-users,
giving an adjusted hazard ratio of 0.67 (0.49 to 0.91). If
these observed benefits translated into clinical practice,
15 patients would need to be treated with a statin for six
months after pneumonia to prevent one death.
Conclusions Compared with people who were not taking
statins, the risk of dying in the six month period after
pneumonia was substantially lower among people who
were already established on long term statin treatment
when the pneumonia occurred. Whether some or all of
this protective effectwouldbeobtained if statin treatment
begins when a patient first develops pneumonia is not
known. However, given that statins are cheap, safe, and
well tolerated, a clinical trial in which people with
pneumonia are randomised to a short period of statin
treatment is warranted.
INTRODUCTION
Statins inhibit hydroxymethyl glutaryl coenzyme A
reductase, which means that they lower blood choles-
terol concentrations and hence reduce the risk of
ischaemic cardiac events.1 2 Over the past decade,
much has been claimed about the possible wide ran-
ging effects of statins.3 Although the pharmacology of
statins theoretically supports a wide range of actions,
many benefits seen in observational studies are possi-
bly due to indication bias and evidence for them has
been inconsistent.4 5
A recent systematic review highlighted a possible
role for statins in the treatment and prevention of
infections.6 The results of nine studies of statin treat-
ment for a range of mostly bacterial infections were
pooled, and a protective effect was found against var-
ious outcomes including sepsis and mortality, with an
odds ratio of 0.55 (95% confidence interval 0.36 to
0.83). This would suggest that patients receiving statins
have less severe outcomes after infection.
We previously reported findings from a large cohort
study comparing users and non-users of statins for a
range of outcomes.4 We validated our study design
by comparing the effects on mortality and cardio-
vascular events seen in our cohort compared with the
effects seen in large randomised trials. The cardio-
vascular effect sizes were remarkably similar, suggest-
ing that we had succeeded in overcoming the selection
bias and confounding that is a common problem in
observational studies of effects of drugs. In our pre-
vious study, we reported a possible reduction in the
incidence of pneumonia among people receiving sta-
tins (hazard ratio 0.84; 99% confidence interval 0.74 to
0.95). In practice, statins would be unlikely to be given
widely to prevent infections because of the very large
numbers of people who would need long term treat-
ment to prevent incident disease. However, statins
may have a more useful role during acute infections,
with the aim of lessening severity. We therefore inves-
tigated the effect of statins onmortality after an episode
of pneumonia.
METHODS
The Health Improvement Network
The Health Improvement Network (THIN) is a data-
base of computerised medical records of general prac-
tices in theUnitedKingdom. It includes diagnostic and
prescribing information, as well as information on var-
ious lifestyle characteristics for more than six million
patients frommore than 300 general practices. Patients
are representative of the general UK population; rates
of pregnancy, consultation, drug prescribing, and
death are similar to national figures,7 and the database
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has been validated for pharmacoepidemiological
research.8
Participants
Themethods used to assemble the cohort for this study
have been described in detail elsewhere.4 Briefly, all
patients aged over 40 years registered in THIN
between January 1995 and December 2006 were eligi-
ble for inclusion. We included in the study all patients
who received their first prescription for a statin on or
after 1 January 1995 and had at least 12 months’ pre-
vious continuous registration in THIN.We termed the
date of first statin prescription the index date. We
matched up to five non-statin users to each statin user
on sex and age within 5 years. Non-users had to be
registered at the same practice as their matched user
on the index date, with at least 12 months’ previous
continuous registration. Non-users had to have no
record of a prescription for a statin before the index
date but could be prescribed a statin later. This
approach avoids selecting a biased control group who
were not at risk of being prescribed a statin. We
required both users and non-users of statins to have
had some form of contact with their practice within
six months before or after the index date to ensure
that all participants were active patients.
Analysis
Propensity score
Apropensity score is ameasure of theprobability that a
patient will be prescribed a certain drug, in this case a
statin, based on the distribution of perceived risk fac-
tors for use among participants who have used and not
used statins. Propensity scores are useful in observa-
tional studies, as they allow the researcher to determine
whether groups of users and non-users are truly com-
parable, and the score can then be used as a way of
handling confounding.9 We calculated propensity
scores for all patients, regardless of whether they sub-
sequently developed pneumonia, by using conditional
logistic regressionwith use of statin at the index date as
the outcome. Factors included in themodel were those
likely to influence the decision to prescribe a statin and
included observation time in THIN; bodymass index;
socioeconomic status; consultation rate; prescribing
rate; smoking status; drinking habits; diabetes; coron-
ary heart disease; cerebrovascular disease; peripheral
vascular disease; other atheroma; other circulatory dis-
ease; dementia; cancer; atrial fibrillation; heart failure;
recent hepatic disease; recent renal disease; thyroid
disease; hyperlipidaemia; hypertension; recent use of
hormone replacement therapy, antipsychotics, anti-
depressants, steroids (oral or inhaled), fibrates, or cyto-
chrome P450 3A4 inhibitors; and any previous use of
non-statin or fibrate lipid lowering drugs, nitrates,
aspirin, β blockers, calcium channel blockers, potas-
sium channel activators, diuretics, positive inotropes,
anticoagulants, antihypertensives, or other cardio-
vascular drugs. As a sensitivity analysis, we also calcu-
lated propensity scores restricted to the reduced cohort
of patients who developed pneumonia.
Propensity scores canbeused to adjust for confound-
ing in several ways.910 Patients with similar scores can
be matched individually, or the score can be adjusted
for in regression analysis. Alternatively, analyses can
be restricted to specific strata within the distribution of
the score.Whichever approach is used, patients should
be included in comparative analyses only if their score
falls within the range common to both users and non-
users, thus avoiding comparisons between patients
with too many differences other than the exposure of
interest. In addition, patientswith scores in the extreme
upper or lower tail of the distribution of scores should
be excluded, as patients may be treated contrary to
their score for important reasons, often missing to the
researcher but related to health outcomes.10 Their
inclusion can therefore lead to biased estimates. We
examined the distribution of scores to ensure that
only patients with scores in common regions of the dis-
tribution were included, and, as a minimum, excluded
those with scores in the upper and lower 5% of the dis-
tribution from analyses. We also did a sensitivity ana-
lysis without this exclusion. From past experience, we
anticipated that the distribution of scores would not
allow efficient matching of users to non-users and
would require adjustment for the score in regression
analyses.We used likelihood ratio testing to determine
whether the score should be treated as a continuous or
categorical variable. We constructed 20 categories of
5% each for this purpose.
Exposure
Two exposures were relevant for this study. Firstly, all
patients included in the primary analysis had to have
had an episode of incident pneumonia after the index
date, as identified by patients’ medical records. For
patients with more than one episode of pneumonia,
we included only the first episode in the analysis. Sec-
ondly, we determined use of statin at the date when
pneumonia was recorded. We considered patients
who had received a prescription for a statin in the
60 day period before pneumonia to be users; we con-
sidered all others to be non-users.
Outcome
The outcome of interest in this studywas all causemor-
talitywithin sixmonths of the incident episodeof pneu-
monia. For patients with at least one episode of
pneumonia after the index date, we ascertained death
from patients’ medical records and defined the date of
death as the earliest of any records indicating that death
had occurred.
Modelling strategy
Firstly, we separated people who died on the day that
pneumonia was diagnosed from those who died later.
This is because pneumonia recorded on the date of
death is likely to represent a contributing factor to the
death rather than an incident diagnosis. Patterns of
recording of cause of death are likely to be influenced
by a patient’s known underlying comorbidities, so dif-
ferences in the likelihood of pneumonia being cited as
RESEARCH
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a cause of death between statin users and non-users are
likely. For this reason, we did no formal analyses on
data frompatientswhodied on the datewhen pneumo-
nia was recorded. For patients who died later or not at
all, the recording of pneumonia is more likely to be
truly incident; we did formal survival analysis for
these patients.
We used Cox regression to model mortality in the
six month period after an episode of pneumonia,
excluding all patients who died on the day of diagnosis
of pneumonia. Right censoring occurred at the earliest
of six months after recording of pneumonia, death, or
the end of the observation period (transfer out of prac-
tice or last data collection date).
We initially adjusted analyses for age in five year
bands and sex. Fully adjusted analyses accounted for
age, sex, propensity score, and year of index date. We
produced a Kaplan-Meir survival curve to investigate
how the risk of death changed over the sixmonths after
pneumonia, excluding deaths on the day of diagnosis.
Table 1 | Characteristics of study population at index date. Values are numbers (percentages)
Characteristics
All patients
Patients with a post-index date episode
of pneumonia
Non-statin users
(n=600 241)
Statin users
(n=129 288)
Non-statin users
(n=7 675)
Statin users
(n=1 398)
Age (years):
40-45 29 221 (4.9) 5 613 (4.3) 110 (1.4) 27 (1.9)
45-50 45 230 (7.5) 9 258 (7.2) 222 (2.9) 25 (1.8)
50-55 71 140 (11.9) 14 548 (11.3) 390 (5.1) 102 (7.3)
55-60 92 756 (15.5) 19 383 (15.0) 604 (7.9) 137 (9.8)
60-65 96 292 (16.0) 20 959 (16.2) 929 (12.1) 189 (13.5)
65-70 90 895 (15.1) 20 748 (16.1) 1 231 (16.0) 238 (17.0)
70-75 74 385 (12.4) 17 527 (13.6) 1 378 (18.0) 299 (21.4)
75-80 53 995 (9.0) 12 228 (9.5) 1 336 (17.4) 225 (16.1)
80-85 31 119 (5.2) 6 230 (4.8) 873 (11.4) 91 (6.5)
85-90 11 980 (2.0) 2 274 (1.8) 463 (6.0) 50 (3.6)
≥90 3 228 (0.5) 520 (0.4) 139 (1.8) 15 (1.1)
Male sex 299 158 (49.8) 65 517 (50.7) 4 058 (52.9) 780 (55.8)
Smoking status:
Non-smoker 201 062 (33.5) 31 578 (24.4) 2 009 (26.2) 280 (20.0)
Ex-smoker 152 273 (25.4) 46 018 (35.6) 1 972 (25.7) 516 (36.9)
Current smoker 221 779 (37.0) 50 383 (39.0) 3 139 (40.9) 592 (42.4)
Unknown 25 127 (4.2) 1 309 (1.0) 555 (7.2) 10 (0.7)
Body mass index:
<20 24 098 (4.0) 2 619 (2.0) 673 (8.8) 48 (3.4)
20-25 175 760 (29.3) 33 971 (26.3) 2 284 (29.8) 370 (26.5)
>25 308 695 (51.4) 83 919 (64.9) 3 080 (40.1) 875 (62.6)
Missing 91 688 (15.3) 8 779 (6.8) 1 638 (21.3) 105 (7.5)
Alcohol consumption:
Non-drinker 80 273 (13.4) 13 236 (10.2) 1 266 (16.5) 186 (13.3)
Ex-drinker 4 428 (0.7) 1 104 (0.9) 82 (1.1) 17 (1.2)
Drinker,quantityunknown 16 795 (2.8) 5 704 (4.4) 231 (3.0) 68 (4.9)
<2 units/day 348 425 (58.1) 76 325 (59.0) 3 870 (50.4) 797 (57.0)
3-6 units/day 64 833 (10.8) 20 525 (15.9) 754 (9.8) 188 (13.5)
>6 units/day 8 751 (1.5) 4 285 (3.3) 174 (2.3) 58 (4.2)
Status unknown 76 736 (12.8) 8 109 (6.3) 1 298 (16.9) 84 (6.0)
Comorbidities:
Atherosclerosis 68 358 (11.4) 63 607 (49.2) 1 965 (25.6) 986 (70.5)
Heart failure 12 946 (2.2) 6 551 (5.1) 711 (9.3) 218 (15.6)
Hypertension 173 101 (28.8) 68 538 (53.0) 2 567 (33.5) 753 (53.9)
Dementia 3 932 (0.7) 329 (0.3) 226 (2.9) 10 (0.7)
Cancer 32 535 (5.4) 6 246 (4.8) 742 (9.7) 93 (6.7)
Diabetes 53 955 (9.0) 35 699 (27.6) 953 (12.4) 450 (32.2)
Drugs:
Antipsychotics 10 360 (1.7) 1 552 (1.2) 394 (5.1) 22 (1.6)
Antidepressants 56 947 (9.5) 15 165 (11.7) 1 188 (15.5) 222 (15.9)
Aspirin 68 776 (11.5) 62 728 (48.5) 1 785 (23.3) 871 (62.3)
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To illustrate the observed effect size, we calculated the
number needed to treat (NNT) by using the equation
NNT=1/(risk among non-statin users with pneumonia
−risk among statin users with pneumonia). For com-
parison, we also used the same approach to model
the effect of statin use on all cause mortality in all
patients, regardless of pneumonia status, after the
index date. We used Stata 11 for all analyses.
RESULTS
Wematched 129 288 people who had received a statin
to 600 241 people not prescribed a statin (the complete
cohort). Smeeth et al give a detailed breakdown of
patients’ characteristics among statin users and non-
users.4 Table 1 shows background information in the
entire cohort and in the patients with a diagnosis of
pneumonia.Among these, 9121 people had an episode
of incident pneumonia after the index date (date of first
statin prescription in statin users). In 137 cases, death
was recorded before pneumonia. Of these, 109 had a
period of 35 days or shorter between recorded death
and pneumonia, indicating that pneumonia may have
been recorded as a possible cause of death. In these
cases, we brought the date of pneumonia forward to
the date of death. The remaining 28 cases had a longer
time lag between recorded death and pneumonia, and
we excluded them from further consideration owing to
uncertainty about the accuracy of dating of events. For
a further 23 patients, the recorded end of observation
occurred before the record of pneumonia. In these
patients, pneumonia was possibly a retrospective
recording. Where the period between end of observa-
tion and pneumonia was 35 days or shorter, we
changed the date of pneumonia to the end of observa-
tion (n=4). For longer periods, we excluded patients
from further analyses owing to uncertainty about accu-
racy of dating (n=19). This left 9073 patients, of whom
1398 (15%) were receiving a statin at the time of diag-
nosis of pneumonia and 7675 were not receiving a sta-
tin. Table 1 also gives descriptive characteristics of the
patients with pneumonia. Of note, 4869/9073 (54%)
people with pneumonia were aged 70 years or older
comparedwith 213 486/729 529 (29%) in the complete
cohort. Patients with pneumonia were alsomore likely
to have a history of atherosclerosis (2957/9073 (33%) v
131 965/729 529 (18%)) or heart failure (929/9073
(10%) v 19 497/729 529 (3%)).
Very few patients who used statins had propensity
scores in the lower eight 5% propensity score bands,
as shown in table 2; further analysis therefore excluded
patients with scores in these bands, in addition to the
20th band, to ensure that we drew comparisons only
between patients with scores in the range seen in both
users and non-users of statins. After this restriction, the
cohort consisted of 942 statin users and 3615 non-
users, of whom 204 users and 1264 non-users died
within six months of the date pneumonia was
recorded. Among these patients, 95 (10%) users and
686 (19%) non-users died on the day pneumonia was
recorded. A further 109 (13%) of the 847 remaining
users and 578/2927 (20%) non-users died later during
the sixmonth follow-up period andwere entered in the
survival analysis (table 3).
The rate ratio for mortality over six months, exclud-
ing deaths on the day of diagnosis of pneumonia, was
0.62 (99% confidence interval 0.47 to 0.81), adjusted
for age and sex and comparing statin users with non-
users. The fully adjusted rate ratio was 0.67 (0.49 to
0.87). The figure shows the crude Kaplan-Meier survi-
val estimates for statin users and non-users, excluding
deaths on the date of diagnosis of pneumonia. A sensi-
tivity analysis using propensity scores calculated only
among patients who developed pneumonia gave a
Table 2 | Distribution of propensity scores*
Propensity
score in
20 groups*
Non-statin users Statin users
No (%) Deaths (%) No (%) Deaths (%)
1 576 (7.5) 86 (15) 1 (0.07) 1 (100)
2 576 (7.5) 91 (16) 2 (0.14) 0
3 496 (6.5) 81 (16) 2 (0.14) 0
4 470 (6.1) 80 (17) 2 (0.14) 0
5 498 (6.5) 69 (14) 1 (0.07) 0
6 451 (5.9) 63 (14) 5 (0.36) 1 (20)
7 425 (5.5) 52 (12) 6 (0.43) 0
8 449 (5.9) 66 (15) 4 (0.29) 0
9 374 (4.9) 55 (15) 8 (0.6) 2 (25)
10 404 (5.3) 73 (18) 13 (0.9) 2 (15)
11 390 (5.1) 56 (14) 17 (1.2) 4 (24)
12 368 (4.8) 55 (15) 22 (1.6) 3 (14)
13 333 (4.3) 51 (15) 24 (1.7) 2 (8)
14 325 (4.2) 56 (17) 39 (2.8) 2 (5)
15 311 (4.1) 53 (17) 36 (2.6) 2 (6)
16 325 (4.2) 62 (19) 83 (5.9) 15 (18)
17 365 (4.8) 61 (17) 145 (10.4) 14 (10)
18 250 (3.3) 32 (13) 239 (17.1) 31 (13)
19 170 (2.2) 24 (14) 316 (22.6) 32 (10)
20 119 (1.6) 9 (8) 433 (31.0) 48 (11)
*1=lowest likelihood of receiving statin; 20=highest likelihood of
receiving statin; based on factors included in propensity score.
Analysis time (months)
A
li
ve
 (%
)
0 1 2 3 4 5 6
2927
No statin
Number at risk
2675 2497 2376 2285 2184 2103
847
Statin
822 784 759 724 698 674
0
70
80
90
100
Statin users
Non-users
Kaplan-Meier survival estimates showing crude mortality
estimates (with 95% confidence intervals) in six months after
episode of pneumonia in statin users and non-users,
excluding deaths on day of diagnosis
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fully adjusted rate ratio of 0.65 (0.49 to 0.87). By con-
trast, a comparison of patients who stopped taking a
statin with those who never started taking one gave a
fully adjusted rate ratio of 0.82 (0.50 to 1.36) for all
further deaths in the next sixmonths. This could reflect
a loss of protective effect due to stopping statin treat-
ment, although uncontrolled differences between
groups may also have contributed to the null effect
seen. A sensitivity analysis including patients with a
score in the 20th 5% score band yielded a similar result
to the primary analysis, with a hazard ratio of 0.72 (0.54
to 0.96). A sensitivity analysis stratified on propensity
score did not suggest that the result was restricted to
any particular region of the score distribution (see
web appendix).
Consideringmortality in the complete cohort, 4718/
51 397 (9%) patientswhowere prescribed a statin at the
index date died during follow-up compared with
32 445/308 730 (11%) not prescribed a statin, after
restriction of analysis to patients within propensity
score bands 9 to 19. The rate ratio for mortality,
adjusted for age and sex, comparing statin users with
non-users was 0.95 (0.91 to 0.99). The fully adjusted
rate ratio was 0.82 (0.79 to 0.86).
Number needed to treat
If the estimated effect was seen in a randomised trial,
the number needed to treat to prevent death within six
months of an episode of pneumonia episode would be
1/((578/2927)−(109/847))=15.
DISCUSSION
Comparedwith peoplewhowere not taking statins, the
risk of dying in the six month period after pneumonia
was substantially lower among people who were
already established on long term statin treatment
when the pneumonia occurred, with a hazard ratio of
0.67 (99% confidence interval 0.49 to 0.91). The effect
seen seems to be greater than the effect of statins on all
cause mortality regardless of pneumonia status, which
was 0.82 (0.79 to 0.86) in this cohort.
Strengths and limitations of study
A major strength of this study is the large cohort size;
nearly 5000 episodes of pneumonia were included in
the main analysis, and around 1000 of these were in
patients prescribed statins. In observational studies of
effects of drugs, a major problem is ensuring that con-
founding by indication has been dealt with so that the
result is likely to represent an effect of the drug rather
than fundamental differences between treated and
untreated people. We were able to adjust for a large
number of confounders by using propensity scores;
this approach can successfully account for much con-
founding by indication. By examining the distribution
of scores separately in the statin users and non-users,
we were able to restrict our main analysis to people
with a similar likelihood of receiving a statin. This is
an advantage of propensity score methods compared
with more traditional multivariate analysis, in which
the comparability of users and non-users can be more
difficult to determine.
As with all observational studies, we cannot be cer-
tain that the effects we observed are causally related to
the use of statins. Although the possibility of residual
confounding by indication and other biases can never
be ruled out, we believe that when making observa-
tions among statin users and non-users, vascular events
are likely to be subject to the most substantial con-
founding by indication. We have previously shown a
protective effect against myocardial infarction and
stroke in this dataset, similar to the effect detected in
clinical trials.4 Moreover, for confounding by indica-
tion to explain these results people at higher risk of
severe pneumonia would have to be preferentially
not prescribed statins. Although people with immuno-
compromising illness may be treated less often for
reduction of lipids, this could be expected to lead to a
similar bias for mortality after influenza as well as
pneumonia. We previously reported no benefit of sta-
tin treatment for complications or mortality after influ-
enza; a point estimate of 0.84 suggested no extra
benefit compared with the generally expected benefit
of statins against mortality.4 This suggests that our
approachmay have successfully eliminatedmuch con-
founding by indication, although obviously this is not
absolutely certain.
For this study, we chose to consider deaths on the
day of diagnosis of pneumonia separately from deaths
that occurred later, as in these cases pneumonia may
have been recorded only because it was given as a
cause of death. We were concerned that pneumonia
could be cited as a cause of death in a way that system-
atically differs between statin users and non-users.
Recording of pneumonia as a cause of death has been
problematic in the UK until very recently, when speci-
fic guidance was issued for certification of death.11
A degree of misclassification of exposure and out-
come may have occurred in this study. General practi-
tioners may not have recorded some episodes of
pneumonia (for example, if a patient was admitted to
hospital and died shortly after, without pneumonia
being noted on the death certificate). Assuming that
such misclassification was similar for statin users and
non-users, this would be expected to lead to a reduc-
tion in power only. Alternatively, some patients could
Table 3 | Association between use of statin and mortality
Outcome No of patients No (%) deaths
Age and sex adjusted
effect estimate: hazard
ratio (99% CI)
Fully adjusted effect
estimate: hazard ratio
(99% CI)
Mortality on day of pneumonia diagnosis
Did not use statin 3 615 686 (19)
Used statin 942 95 (10)
Mortality within 6 months of pneumonia, excluding deaths on day of pneumonia*
Did not use statin 2 927 578 (20) – –
Used statin 847 109 (13) 0.62 (0.47 to 0.81) 0.67 (0.49 to 0.91)
All mortality after index date (regardless of pneumonia status)*
Did not use statin 308 730 32 445 (11) – –
Used statin 51 397 4 718 (9) 0.95 (0.91 to 0.99) 0.82 (0.79 to 0.86)
*Analysis restricted to patients with comparable propensity scores.
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have been incorrectly diagnosed as having pneumo-
nia, which would result in a bias towards the null.
Bias could also be introduced if pneumonia was
recorded differently among statin users and non-
users. Unfortunately, we could not ascertain the com-
pleteness and validity of recording of pneumonia in
this study.
Recording of mortality in THIN is comparable with
UK-wide rates,7 but some deaths may not have been
recorded. Again, this is unlikely to have differed
according to statin use and would therefore be
expected to bias any result towards the null. Finally,
use of statins is of vital importance; the primary analy-
sis allocated statin use as determined by prescription
rather than consumption. Some patients do not take
their drugs as prescribed, so, at the time pneumonia
occurred, a small proportion of patients may be mis-
classified as statin users. However, more than 99% of
patients taking statins had received two or more pre-
scriptions for statins, and repeat prescribing is likely to
represent genuine drug use in most cases. Misclassifi-
cation of statin use is also unlikely to have differed
according to mortality status, so we would expect the
effect to be a bias towards the null. The observed pro-
tective effect of statins seemed to be much diminished
or absent when we compared patients who stopped
their statin with those who never started. Caution is
needed in the interpretation of this result, however, as
people who stop their statin may differ fundamentally
from those who continue treatment, in ways that are
directly related to underlying health.
Comparison with other studies
Observational studies in other populations have
looked at the effect of statins in the treatment of pneu-
monia but have had limited power.Our results seem to
be largely in keeping with those reported elsewhere.
Four studies identified a protective effect when com-
paring statin userswith non-users.Almog et al reported
an odds ratio of 0.07 (0.01 to 0.51) for severe sepsis in
patients with bacterial infections (50% of which were
pneumonia), although the enormous magnitude of
effect detected in this study suggests possible residual
confounding.12 Frost et al found a hazard ratio of 0.61
(0.41 to 0.92) for mortality due to influenza/pneumo-
nia, although what proportion of these cases were
pneumonia is unclear.13 Mortensen et al reported an
odds ratio of 0.48 (0.36 to 0.64) for mortality 30 days
after pneumonia.14 Myles et al found a hazard ratio of
0.33 (0.19 to 0.58) for all causemortalitywithin 30 days
of pneumonia.15Of note, this study also used data from
THIN but included only 12 fatal cases among statin
users, compared with 216 in our study. In contrast,
Majumdar et al found an odds ratio of 1.1 (0.76 to
1.6) for all cause mortality after admission to hospital
for community acquired pneumonia.16 This study
seems to be well conducted, and the investigators
were able to account formanyunderlying factors likely
to differ between statin users and non-users. The rea-
sons for such differences in results are not clear.
Implications of findings
Our study was able tomeasure only the effect of statins
as given before pneumonia developed; in many
instances statin treatment had been ongoing for a
long period of time. For these findings to be of direct
clinical relevance, whether a short course of statin
treatment started at the time of diagnosis of suspected
pneumonia improves the chances of survival would
need to be determined. A growing body of evidence
shows that statins exert rapid effects; endothelial func-
tion and arterial flow improve within 24 hours of start-
ing a statin,17 and inflammatory markers such as C
reactive protein are reduced with three days.18
Our studywas not designed to assess themechanism
of any observed protective effect. However, statins are
known to affect the cell signallingpathways involved in
immune and anti-inflammatory responses, which
could lead to a reduction in severity of infection in
some cases.19
Statins are safe,20 cheap, and an easy intervention in
terms of delivery. Given the potential low number
needed to treat to prevent a death suggested by this
study, we believe that a strong case exists for rando-
mised trials of statins in people with serious infection
to determine if a simple and practical intervention at
the point of diagnosis of pneumonia has a beneficial
effect.21 22 A trial of around 3000 people randomised
to a statin or placebo at the time of diagnosis of pneu-
monia would be needed to determine whether a short
period of statin treatment could reduce mortality by
20% among people with suspected pneumonia. Such
a trial would be able to look in detail at specific causes
of death, which may further elucidate a possible
mechanism for any beneficial effect.
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